Overview
Optimizing Patient Outcomes in Pancreatic Cancer With Al B. Benson, MD, FACP, FASCO
With 5-year survival rates of only 37% for local disease, 12% for regional disease, and 3% for distant disease, pancreatic cancer is one of the most aggressive forms of cancer and one of the most challenging to treat. Despite the development of novel treatment approaches, therapeutic options remain limited. In this episode of Oncology Data Advisor, Al B. Benson, MD, Professor of Medicine at Northwestern University’s Feinberg School of Medicine and Associate Director for Cooperative Groups at Northwestern’s Robert H. Lurie Comprehensive Cancer Center, joins i3 Health for a discussion that covers recent developments in genomic testing and targeted therapies, supportive care measures that can optimize quality of life, and strategies that members of the cancer care team can utilize to improve the outcomes of their patients with pancreatic cancer.
TARGET AUDIENCE
Oncologists, gastroenterologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with pancreatic cancer.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Identify the role that biomarkers can play in predicting therapeutic efficacy and developing tailored approaches to treatment
- Develop effective multidisciplinary approaches that can be used to enhance pancreatic cancer treatment and supportive care
FACULTY
Al B. Benson, MD, FACP, FASCO
Professor of Medicine
Northwestern University Feinberg School of Medicine
REGISTRATION
There is no fee to participate in or claim CME credit for this activity.
Provided by
Physicians
i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
i3 Health designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.
Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
ONCC RECERTIFICATION
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply .25 ILNA points toward:
- Diagnosis and Staging
- Disease-Related Biology
- Scientific Basis for Practice
- Symptom Management
- Treatment
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with commercial interests that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Dr. Benson discloses that he serves on an advisory board or panel for Amgen, Array BioPharma, Artemida, Bristol Myers-Squibb, Guardant, Imedex, Lexicon, Merck Sharpe & Dohme, Terumo, and TheraBionic. He also receives grants or other research support from Astellas, Bristol Myers-Squibb, Celgene, Infinity Pharmaceuticals, Medimmune, Merck Sharpe & Dohme, Rafael Pharmaceuticals, SynCore, Taiho Pharmaceuticals, and Xencor.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
- Listen to the podcast
- Take the posttest
- Download or print their Certificate of Credit
UNAPPROVED USE DISCLOSURE
i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
DISCLAIMER
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at This email address is being protected from spambots. You need JavaScript enabled to view it..